RadNet, Inc.
RDNT
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $5.8B
$73.71
▼ -1.22%
P/E
-275.24
Mkt Cap
$5.8B
52-Wk Range
$50.82–$85.84
52-Week Range
$50.82 - $85.84
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 2.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Largest independent outpatient imaging network with 347 centers providing significant scale and operational leverage
- Proprietary AI and software solutions creating recurring revenue streams and customer lock-in
- Established relationships with referring physicians, hospitals, and health systems across seven states
- Integrated platform combining high-volume imaging with technology solutions, difficult for competitors to replicate
Bear Case
2 risks
- Average volatility.
- Extreme premium - high expectations embedded
Growth
Turning profitable
Expansion of AI-powered diagnostic tools driving higher margins and customer stickiness
Value
Extreme premium - high expectations embedded
Momentum
Hot
+36.1% over 3m
Quality
Thin
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying RDNT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 9, 2026
Reported EPS of $0.29 vs $0.20 consensus (+44.0% surprise). Revenue of $622.7M vs $610.9M expected (+1.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+44.0%
Revenue trend · last 8Q
—
+13%
+9%
+8%
+13%
+15%
+22%
+25%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$461.1M
$477.1M
$471.4M
$498.2M
$522.9M
$547.7M
$575.6M
$622.7M
Margins · last 8Q
Gross
2.6%
Operating
5.1%
Profit
2.7%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Barclays · Aug 28, 2026
vs Industry
How RDNT stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related